Codexis Announces New Employment Inducement Grants
Codexis (NASDAQ: CDXS) has announced the approval of equity grants for five new employees, as approved by the company's Board of Directors' Compensation Committee. The inducement awards, granted under the 2024 Inducement Plan, include:
Stock Options: 39,000 shares with an exercise price matching Codexis' Nasdaq closing price on grant date. These vest over four years, with 25% vesting after one year and the remainder vesting monthly.
Restricted Stock Units (RSUs): 27,500 units vesting in equal annual installments over three years. Both grants are subject to continued employment with Codexis through applicable vesting dates.
Codexis (NASDAQ: CDXS) ha annunciato l'approvazione di concessioni azionarie per cinque nuovi dipendenti, come approvato dal Comitato per la Compensazione del Consiglio di Amministrazione dell'azienda. I premi di induzione, concessi nell'ambito del Piano di Induzione 2024, includono:
Opzioni su azioni: 39.000 azioni con un prezzo di esercizio che corrisponde al prezzo di chiusura di Codexis su Nasdaq alla data di concessione. Queste si maturano in quattro anni, con il 25% che si matura dopo un anno e il restante che si matura mensilmente.
Unità azionarie vincolate (RSU): 27.500 unità che si maturano in rate annuali uguali nel corso di tre anni. Entrambi i premi sono soggetti a un'occupazione continuativa con Codexis fino alle date di maturazione applicabili.
Codexis (NASDAQ: CDXS) ha anunciado la aprobación de concesiones de acciones para cinco nuevos empleados, según lo aprobado por el Comité de Compensación de la Junta Directiva de la empresa. Los premios de inducción, otorgados bajo el Plan de Inducción 2024, incluyen:
Opciones de acciones: 39,000 acciones con un precio de ejercicio que coincide con el precio de cierre de Codexis en Nasdaq en la fecha de concesión. Estas se consolidan durante cuatro años, con un 25% consolidándose después de un año y el resto consolidándose mensualmente.
Unidades de acciones restringidas (RSUs): 27,500 unidades que se consolidan en cuotas anuales iguales durante tres años. Ambas concesiones están sujetas a la continuidad del empleo con Codexis hasta las fechas de consolidación aplicables.
Codexis (NASDAQ: CDXS)는 회사의 이사회 보상위원회의 승인을 받아 다섯 명의 신규 직원에 대한 주식 보상을 승인했다고 발표했습니다. 2024 유인 계획에 따라 부여된 유인 보상에는 다음이 포함됩니다:
주식 옵션: 부여일의 Codexis 나스닥 종가에 해당하는 행사 가격으로 39,000주. 이는 4년에 걸쳐 분할되며, 1년 후에 25%가 확정되고 나머지는 매달 확정됩니다.
제한 주식 단위 (RSU): 27,500 단위가 3년에 걸쳐 동일한 연간 할부로 확정됩니다. 두 가지 보상 모두 해당 확정 날짜까지 Codexis에서의 지속적인 고용에 따라 달라집니다.
Codexis (NASDAQ: CDXS) a annoncé l'approbation de concessions d'actions pour cinq nouveaux employés, comme approuvé par le Comité de Rémunération du Conseil d'administration de l'entreprise. Les récompenses d'incitation, accordées dans le cadre du Plan d'Incitation 2024, comprennent :
Options d'actions : 39 000 actions avec un prix d'exercice correspondant au prix de clôture de Codexis sur Nasdaq à la date de concession. Celles-ci sont acquises sur quatre ans, avec 25 % acquises après un an et le reste acquis mensuellement.
Unités d'actions restreintes (RSU) : 27 500 unités acquises en versements annuels égaux sur trois ans. Les deux concessions sont soumises à un emploi continu chez Codexis jusqu'aux dates d'acquisition applicables.
Codexis (NASDAQ: CDXS) hat die Genehmigung von Aktienzuwendungen für fünf neue Mitarbeiter bekannt gegeben, die vom Vergütungsausschuss des Vorstands des Unternehmens genehmigt wurden. Die Anreizvergütungen, die im Rahmen des Anreizplans 2024 gewährt werden, umfassen:
Aktienoptionen: 39.000 Aktien mit einem Ausübungspreis, der dem Schlusskurs von Codexis an der Nasdaq am Gewährungstag entspricht. Diese erwerben sich über vier Jahre, wobei 25% nach einem Jahr und der Rest monatlich fällig wird.
Eingeschränkte Aktieneinheiten (RSUs): 27.500 Einheiten, die in gleichen jährlichen Raten über drei Jahre fällig werden. Beide Zuwendungen unterliegen der fortdauernden Beschäftigung bei Codexis bis zu den jeweiligen Fälligkeitsterminen.
- Employee retention strategy through equity compensation
- Structured vesting schedule promotes long-term commitment
- Potential shareholder dilution from new equity issuance
REDWOOD CITY, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 39,000 shares of Codexis common stock and (ii) 27,500 restricted stock units (RSUs) as inducement awards under the Company’s 2024 Inducement Plan.
The stock options have an exercise price equal to the closing price per share of Codexis’ common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 percent of the shares vesting on the first anniversary of the vesting commencement date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to each employee’s continued service with Codexis through the applicable vesting dates. The RSUs will vest in equal annual installments on each anniversary of the grant date, until the third anniversary of such date, subject to each employee’s continued service with Codexis through the applicable vesting dates.
Codexis is providing this information in accordance with Nasdaq Listing Rule 5635(c)4.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule and nucleic acid therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
FAQ
How many shares of stock options did Codexis (CDXS) grant in their February 2024 inducement awards?
What is the vesting schedule for Codexis (CDXS) 2024 inducement RSUs?
How many RSUs did Codexis (CDXS) issue in their February 2024 inducement grants?
What is the vesting schedule for Codexis (CDXS) 2024 inducement stock options?
